Literature DB >> 2598991

Computer analysis of saccadic eye movements: assessment of two different carbamazepine formulations.

G Tedeschi1, G Casucci, S Allocca, R Riva, A Di Costanzo, A Quattrone, A Baruzzi, V Bonavita.   

Abstract

The central effects of two different formulations of Carbamazepine (CBZ) have been examined by analysis of saccadic eye movements (SEM) in 6 healthy volunteers, who took part in a double-blind, latin-square, placebo controlled study. Both a conventional- and a controlled-release formulation of CBZ produced a significant effect on peak saccadic velocity and saccade accuracy, but only the former affected saccade latency. Computer analysis of SEM confirmed it to be a highly sensitive method for detection of subclinical drug effects on the CNS.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2598991     DOI： 10.1007/bf00558133

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  17 in total

1.  Treatment with carbamazepine: children.

Authors:  I Gamstorp
Journal:  Adv Neurol       Date:  1975

2.  Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance.

Authors:  A N Griffiths; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

3.  Bioavailability and central side effects of different carbamazepine tablets.

Authors:  P J Neuvonen
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-04

4.  Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies.

Authors:  K K Chan; R J Sawchuk; T A Thompson; E Redalieu; W E Wagner; A R LeSher; B J Weeks; N R Hall; A Gerardin
Journal:  J Pharm Sci       Date:  1985-08       Impact factor: 3.534

5.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

6.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

7.  Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Ambrosetto; G Procaccianti; M Santucci; A Baruzzi
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

8.  Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

Authors:  T Tomson
Journal:  Arch Neurol       Date:  1984-08

9.  Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients.

Authors:  G J Macphee; E M McPhail; E Butler; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy.

Authors:  D G Andrewes; J G Bullen; L Tomlinson; R D Elwes; E H Reynolds
Journal:  Epilepsia       Date:  1986 Mar-Apr       Impact factor: 5.864
View more
  3 in total

1.  Perturbed reward processing in pediatric bipolar disorder: an antisaccade study.

Authors:  Sven C Mueller; Pamela Ng; Veronica Temple; Michael G Hardin; Daniel S Pine; Ellen Leibenluft; Monique Ernst
Journal:  J Psychopharmacol       Date:  2010-01-15       Impact factor: 4.153

2.  Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of the liquid suspension to naive subjects.

Authors:  J D Wildin; B J Pleuvry; G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

Review 3.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.